At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
JUNS Jupiter Neurosciences
Trading 08-27 09:35:19 EDT
4.95
-0.06
-1.20%
High4.98Low4.94Vol15.27K
Open4.96D1 Closing5.01Amplitude0.80%
Mkt Cap3.81MTradable Cap2.64MTotal Shares770.10K
T/O75.75KT/O Rate2.86%Tradable Shares533.80K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Jupiter Neurosciences Gains Relief from Insider Debt Forgiveness
TIPRANKS  ·  18:58
Jupiter Neurosciences Gains Relief from Insider Debt Forgiveness
Jupiter Neurosciences Executives Forgive $875,315 in Accrued Unpaid Compensation
Reuters  ·  18:34
Jupiter Neurosciences Executives Forgive $875,315 in Accrued Unpaid Compensation
Top Premarket Decliners
MT Newswires Live  ·  08-25 19:34
Top Premarket Decliners
Jupiter Neurosciences Completes Capital Raise Supporting Nasdaq Listing
TIPRANKS  ·  08-25 05:32
Jupiter Neurosciences Completes Capital Raise Supporting Nasdaq Listing
Jupiter Neurosciences Says $2 Million Stock Sale Lifts Equity Above NASDAQ Minimum Listing Threshold
Reuters  ·  08-25 04:53
Jupiter Neurosciences Says $2 Million Stock Sale Lifts Equity Above NASDAQ Minimum Listing Threshold
US Equity Indexes Rise Despite Surging Bond Yields as US Nears Tariff Deal With Canada
MT Newswires Live  ·  08-22
US Equity Indexes Rise Despite Surging Bond Yields as US Nears Tariff Deal With Canada
Why Is Penny Stock Jupiter Neurosciences (JUNS) Up Today?
TIPRANKS  ·  08-22
Why Is Penny Stock Jupiter Neurosciences (JUNS) Up Today?
Jupiter Neurosciences Prices USD 2 Million Registered Direct Offering of 307,692 Shares
Reuters  ·  08-22
Jupiter Neurosciences Prices USD 2 Million Registered Direct Offering of 307,692 Shares
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
THOMSON REUTERS  ·  08-22
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
NASDAQ Trade Halt Volatility Trading Pause at 10:02 Am
Reuters  ·  08-21
NASDAQ Trade Halt Volatility Trading Pause at 10:02 Am
Jupiter Neurosciences FY26 Q2 Net Loss Widens 0.95% to $2.27 Million; Revenue Totals $24,245
Reuters  ·  08-15
Jupiter Neurosciences FY26 Q2 Net Loss Widens 0.95% to $2.27 Million; Revenue Totals $24,245
Jupiter Neurosciences Inc trading halted, news pending
TIPRANKS  ·  08-07
Jupiter Neurosciences Inc trading halted, news pending
NASDAQ Trade Halt Halt News Pending at 07:50 Pm
Reuters  ·  08-07
NASDAQ Trade Halt Halt News Pending at 07:50 Pm
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
THOMSON REUTERS  ·  08-05
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
Jupiter Neurosciences Raises Capital Through Equity Offering
TIPRANKS  ·  07-29
Jupiter Neurosciences Raises Capital Through Equity Offering
Jupiter Neurosciences Sells 11,470,000 Shares to Yorkville for About $3.6 Million in Unregistered Offering
Reuters  ·  07-29
Jupiter Neurosciences Sells 11,470,000 Shares to Yorkville for About $3.6 Million in Unregistered Offering
Jupiter Neurosciences Held Annual Shareholder Meeting, with 59% of Shares Represented
Reuters  ·  07-27
Jupiter Neurosciences Held Annual Shareholder Meeting, with 59% of Shares Represented
Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences
TIPRANKS  ·  07-23
Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences
Jupiter Neurosciences Director Andrew Jon Cutler Files Initial Beneficial Ownership Statement
Reuters  ·  07-23
Jupiter Neurosciences Director Andrew Jon Cutler Files Initial Beneficial Ownership Statement
Jupiter Neurosciences Licenses ALA-002 for U.S. Development
TIPRANKS  ·  07-22
Jupiter Neurosciences Licenses ALA-002 for U.S. Development

Introduction

Company Name.
Jupiter Neurosciences
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Jupiter Neurosciences, Inc. was incorporated in Delaware in January 2016. The company is a clinical-stage R&D company focused on developing treatments for neuroinflammation using its proprietary resveratrol formulation, JOTROL. Its primary therapeutic target is Parkinson's disease, for which it plans to conduct a Phase IIa clinical trial, and it has launched a consumer-facing product line called Nugevia focused on longevity and wellness.
Issue price:
--